Method of producing sodium salts of muramylpeptide derivatives

专利摘要:
The invention relates to peptide derivatives, in particular to the CHCHZORe OR8 + E-NHNHC {0) Ri RXH-C
公开号:SU1277906A3
申请号:SU813350700
申请日:1981-10-29
公开日:1986-12-15
发明作者:Тарчай Лайос；Башанг Герхард；Хартманн Альберт；Станек Ярослав
申请人:Циба-Гейги Аг. (Фирма)；
IPC主号:

专利说明:

11277906
related to the way of biologically active, namely sodium x muramyl peptides
my si me
5 ce su ku vayu
Ri-f
ONH-CH-CONH-CH-CHjCH7COA
(L) (D)
R (- C -, - C-alkyl, Rj - hydrogen, CH ,; R} - C, -C4-alkyl-,
ABOUT ,
-Y-O-P-O-CH -CH-CH -RS
ONa Rii
where Y is -0-CHj, 4: ONHCH CH, -,
-NHCH CHj -, -NH-CH (CH) -CONHCH (L)
V
 By using an Amicon type YM 1 membrane, diaphi-ptratation is applied sequentially with 400 ml of water, 200. a mixture of 0.1 M sodium phosphate buffer 0.1 M solution of NaCJ (pH 7.0), 850 water. Internal dialysate filter through a Teflon filter type M then (0.45 microns). The filtrate is dried. filno The result is 1.08
20
25
R. is hydrogen, (rmt h hdd; "(91%) of the compound, M +13.9 and L.) l / t-CHo,; 30 (C i, 0i acetic acid).
(CH2) i / i.-CH3
Found,%: C 53.89; H 8.63; N 6.40; P 2.22i Na 1.58. PNa 3 N, 0
ABOUT
The purpose of the invention is to obtain new derivatives of muramyl peptides, which have a higher immunostimulating activity in combination with low toxicity.
Example 1. Sodium salt of N- -acetyl-muramyl-b-alanyl-B-isoglutaminyl-b-alanine-2- (1,2-dipalmitoyl-5p-glycero-3-phosphoryl) -eth: Yes 1).
To 1.0 mmol of 1-o6-benzsh1-N-acetyl-4,6-isopropylidene-muraminic acid and 0.9 mmol of L-alanyl-B-isoglutaminyl-1 -, - alanine-2- (1, 2 -dipalmiJ5. Calculated, C 53.59; H 8.75; N 6.40; P 2.36; Na 1.75.
Example 2. Sodium salt of H-acetyl-muramyl-b-alanyl-B-isoglutamine-b-alanine-2- (1,2-dipalmito
4 (3 il-3n-glycero-3-phosphoryl) -ethyl-amide (1).
To a solution of 1.0 mmol of B-isoglutaminyl-b-alanine-2- (1,2, dipolarmitoyl-3p-glycero-3-phosphoryl) -ethylamide
45 and 3.5 mmol of K-eti.pmorfolina in 25 ml of a mixture of chloroform - methanol - water (65: 25: 4) are added dropwise 1.5 mmol of N-hydroxycyclate N-acetyl-muramyl-b-alanine in 5, About ml
, toyl-8p-glycero-3-phosphoryl) -ethylamine-50 dimethylacetamide. The reaction mixture, in a mixture of 15 ml of dimethylformamide, was stirred for 8 hours at room temperature on a silica gel column chromatography (Merck) using chloroform-methanol (7: 3) as eluent. Fractions containing
The target product is evaporated. A mixture of 12 MP of glacial acetic acid and 8 ml of water is added to the residue, kept at 50 ° C for 1. h, and then hydrogenated for 20 hours at room temperature and atmospheric pressure in the presence of 10% palladium on coal Then the catalyst is filtered off, the filtrate is evaporated in vacuo, the residue is dissolved in -150 ml of water.
The resulting solution was filtered through a Millipore teflon filtrate (5 μm). The filtrate is dialyzed with stirring in an Amfikon ultrafiltration cell using an Amikon YM 10 type membrane using diffusion against 400 ml of water, 200 ml of a mixture of 0.1 M sodium phosphate buffer — 0.1 M NaCJ (pH 7, 0), 850 ml of water. The internal dialysate is filtered through a Millipore-type Teflon filter (0.45 μm). The filtrate is dried lyr. The result is 1.08 g
20
(91%) of the compound, M +13.9 (C i, 0i acetic acid).
Found,%: C 53.89; H 8.63; - 6.40; P 2.22i Na 1.58. PNa 3 N, 0
С5, Н, „N, 0
. Calculated, C 53,59; H 8.75; N 6.40; P 2.36; Na 1.75.
Example 2. Sodium salt of H-acetyl-muramyl-b-alanyl-B-isoglutamine-b-alanine-2- (1,2-dipalmitoyl-3n-glycero-3-phosphoryl) -ethyl-amide (1).
To a solution of 1.0 mmol of B-isoglutaminyl-b-alanine-2- (1,2, dipolarmitoyl-3p-glycero-3-phosphoryl) -ethylamide
and 3.5 mmol of K-eti.pmorfolina in 25 ml of a mixture of chloroform - methanol - water (65: 25: 4) are added dropwise 1.5 mmol of N-hydroxycyclate N-acetyl-muramyl-b-alanine 5 , About ml
10 ml of tetrahydrofuran and 2 ml of pyridine were added with 1.2 mmol of dicyclohexylcarbodiimide and 1.3 mmol of N-hydroxy succinimide. After 24 hours, a few drops of water are added to the reaction mixture, the dicyclohecic urea precipitate is filtered off, the filtrate is evaporated in
130 ml of water was added and evaporated in vacuo to remove chloroform and part of methanol. Leave the 55 aqueous solution filtered through a Millipore Teflon filter (5 μm). The filtrate is dialyzed with ultrafiltration agitation.
vacuum to dryness. The residue is purified in an Amikon cell using memory, 130 ml of water are added and evaporated in vacuo to remove chloroform and a portion of methanol. Leave the 55 aqueous solution filtered through a Millipore Teflon filter (5 μm). The filtrate is dialyzed with ultrafiltration agitation.
3
Amicon type YM 10 using diafiltration sequentially against 400 MP of water, 200 MP of a mixture of 0.1 M sodium phosphate buffer-0.1 M NaCi solution (pH 7.0) and 850 ml of water. Internal dialysate is filtered through a Millipore teflon filter (0 , 45 microns). The filtrate is dried lyophilic. As a result, 1.20 g (91%) of compound 1 is obtained, Rr 0.29 (chloroform - methanol - water 65: 25: 4) (A), 0.65 (chloroform - methanol - acetic acid - water 25 : 15: 4: 2) (b).
For all other physico-chemical characteristics, the resulting product is fully consistent with



the result obtained in example 1.
Example 3. Sodium salt of K-acetyl-muramyl-b-alanyl-B-isoglutamine-b-alanine-2- (1, 2-dipylaminoyl-8n-glycero-3-phosphoryl) -ethyl amide (T ).
0.26 g (0.75 mmol) of N-acetyl-muramyl-L-alaicna 1.2H20 and 0.172 g (1.5 mmol) of N-hydroxysuccinimide are dissolved in 3.0 ml of absolute dimethyl acetamide. 0.232 g (1.13 mmol of dicyclohexylcarbodiimide) is added to the solution obtained at OC. The reaction mixture is stirred for 8 hours at and a solution of 0.445 g (0.5 mmol of B-isoglutaminyl-L-alanine-2- (1, 2 - -dipalmitoyl-3n-glycero-3-phosphoryl) -ethylamide and 0.07 ml (0.5 mmol) of triethylamine V. 12 ml of a mixture of chloro / form - methanol - water (65: 25: 4). Then the reaction mixture stir for 24 hours at room temperature, add 60 MP of ethyl acetate, stir for several minutes in an ice bath and filter, add 65 MP of water to the filtrate and evaporate the resulting mixture in vacuo to The remaining aqueous solution is dialyzed with stirring in an ultrafiltration cell of the Amikon type using an Amikon YM 10 membrane, successively against 200 ml of water, 100 ml of a 0.1 M sodium phosphate buffer solution (pH 7, 0) and 425 ml of water. The internal dialysate is filtered through a Millipore-type teflon filter (0.45 µm) The filtrate is freeze-dried. A total of 0.546 g (83%) of compound 1, RI 0.45 (acetonitrile — water 3: 1) is obtained. For all other physico-chemical ha

The characteristics of the resulting product are fully consistent with the compound obtained in Example 1.
Example 4. Sodium salt of N- -acetyl-desmethylamine or L-L-alayl-D- -isoglutamine-2- (1, 2-dipipal toyl-Sn-glycero-3-phosphoryl) -ethyl-amide (fl),
From 1.0 mmol of B-isoglutamine-2- (1, 2 -dipalmitoyl-3n-glycero-3 -phosphoryl) -tylamide, -2.8 NO and 1.5 mmol of N-oxysuccinimide ester. Na-methyl-desmethyl-amyl-L-alanine analogously to Example 2, 1.18 g (96%) of Compound II, R, 0.29 (A), 0.65 (B) are obtained.
Found,%: C 53.67, H 8.16; N 5.93i P 2.40; Na 1.71.
С „Н, o, N50, gPNa- 2,8НгО
Calculated,%: C 53.88; H 8.25; N 5.71; P 2.53; Na 1.88.
Example 5. Sodium salt of M-acetyl-muramyl-b-alanyl-B-isoglutaminyl-y-oxy-methylcarbonyl-2- (1, 2-β-dipalmitoyl-3p-glycero-3-phosphoryl) -ethylamide (ly) .
From 1.0 mmol of B-isoglutamine-2-oxy-methylcarbonyl-2- (1, 2-dipalmitoyl-3p-glycero-3-phosphoryl) -ethyl and 1.5 mmol of N-oxysuccinimide ester K-acetyl -muramyl-L-alanine analogously to Example 2, 1.20 g (92%) of the compound HZ, R, 0.28 (A), 0.68 (B) is obtained.
Found,%: C 53.21; H 8.09; N 5.18; P 2.21; Na 1.58;
Sz vNyub N O oPNa- 3.1
Calculated,%: C, 53.40; H 8.13; N 5.37; P 2.38; Na 1.78.
Example 6. Sodium salt of L-acetyl-desmethylmuramyl-b-alanyl- -B-of oglutamine-2- (3 -palmitoyl-rac- -glycero-1-phosphoryl) -ethylamide (ly),
From 1.0 mmol of B-isoglutamine-2- (h - palmitoyl-rac-glycero-1-phosphoryl) - ethylamide and 1.5 mmol of N-oxysucci - N-acetyl-dezimethyrumyl-b-alanine nimido ester, similarly to the example
I
, 2 get 0.69 g (69%) of compound iV, R 0.47 (A).
Found,%: C, 47.22; H 7.17; N 7.31; P 3.01; Na 2.14,
 NjO PNa- 3,2
Calculated,%: C 47.08; H 7.24; N 7.04; P 3.12; - Na 2.31.
PR and M e R 7. The sodium salt of K-acetyl-muramyl-b-alanyl-B-isoglutamine-b-alanine-2- (3-palmitoyl-rac-glycero-1-phosphoryl) -ethyl-amide f .
From 1.0 mmol of B-isoglutaminyl-L- -alanine-2- (3-palmitoyl-rac-glycerol-l-phosphoryl) -ethyl, and 1.51 hmol of N-acetylmuramyl-b N-oxyl succinyl ester -alanine analogously to example 2 receive the compound V, R Oh, 22 (A)
Found,%: C 47.71, H 7.81; N 7.55; P- 2.71-, Na 2.01;
C, H7gNgO, gPNa. 3.1 Calculated,%: C 47.92-, H 7.24; N 7.80; P 2.88; Na 2.1D.
Example 8. The sodium salt of N-acetyl-desmethylmuramyl-b-alanyl-β-B-isoglutaminyl-b-alanine-2- (1, 2-α-dipalmitoyl-3n-glider-3 -phosphoryl) ethylamide (yl),
From 1.0 mmol of B-isoglutaminyl-b- -apanine-2 (1, 2 -dipalmitoyl-Sn-glycero-3 -phosphorus-1) - ethylamide and 1.5 mmol of N-acetyl-de-methyl-methyl-yl N-oxysuccinimide ester -L-alanine analogously to Example 2, 1.065 (82%) of compound VI is obtained, R ± 0.39 (A).
Found,%: C 53.68, H 8.02; N 6.38; P 2.24, Na 1.60
.. PNa- 3N, 0 Calculated,%: C 53.47; H 8.14; N 6.45; P 2.38; Na 1.77.
Example 9. Sodium salt of N-ace t yl-de s-methylmuramyl-L-alanyl-B-iso-glutaminyl-b-alanine-2- (3-pal mitoyl-rac-glycero-1-phosphoryl) -ethyl amide (vfi )
From 1.0 mmol N-isogl aminil-L I
α-alanine-2- (3-palmitoyl-rac-glycero-1-phosphoryl) ethylamide and 1.5 mmol H-nitrophenyl of N-adethyl-β-disme gylmuramyl-b-alanine, analogously to Example 2, compound VII 4 is obtained .J 0.16 (A). The yield of 0.755 g (71%).
Found,%: With 47.48; H 7.09, N 7.80i P - 2.71; Na 2.01-,
C z TeNbOiS PNa- 2, Calculated,%: C 47.66; H 7.19; N 7.94; P 2.93; Na 2.17.
Example 10. Sodium salt of N-acetyl-myramyl-L- (xL-aminobutytersI- -B-isoglutaminyl-b-ala 1In-2- (1, 2-dipolaritoyl-3n-glycero-3-phosphoryl) -ethyl amide ( VIJI).
From 1.0 mmol of B-isoglptaminl-1-β-alanine-2- (1, 2-dipalmitoyl-Sn-β-glycero-3-phosphoryl) -ethylamide, 1.5 mmol of N-acetyl-mypromyl-L-oi, - aminobutyric acid, 2.5 mmol dicyc lehexylcarbodiimide and 3.0 mmol N
| -oxisucdinimide analogously to Example 3, the compound Vlll, RL 0.32 (A) is obtained.
Found,%: C 53.74; H 8.23; N 6.04; P 2.18; Na-1.54,
Sbenzo NbO ,, PNa- 3.93H20
Calculated,%: C 53.56; H 8.18, N 6.25; P 2.31-, Na 1.71.
Example 11. Sodium salt of N propionyl-Normyl-L-alayl-B-isoglutamines 1-b-al; anin-2- (1, 2 -dif-palmitoyl-3p glycero-3-phosphoryl) -ethylamide (IX) .
Out of 1.0 mmol of B-isoglutaminyl-L-α-alanine-2- (1, 2-dipyl of itoyl-Sn-gly-5-cero-3 -phosphoryl) -ethylamide and 1.5 mmol of N-propionyl-N-hydroxyphthalimide -normuramyl-b-alanine analogously to Example 2, 1.15 g (87%) of compound IX, R 0.16 (A), (CO, 547 y-cyclic acid) are obtained.
Found,%: C 53.31; H 8.26; N 6.14; P 2.15; Na 1.55.
C5gH (o8NgO ,, PNa 3,5
Calculated,%: C 53.53, H 8.17; N 6.35; P 2.34, Na 1.74.
Example 12. Sodium salt of N-acetyl-mypamyl-L - alanyl-S-isoglutamine-2- (1, 2-dipole of itoyl-3n-glidero-3-phosphoryl) -ethylamide (X).
From 1.4 mmol of B-isoglute1 shn-2- (1,2-β-dipalmitoyl-Zp-glycero-3-phosphoryl) ethyl amide and 2.0 mmol of the N-oxysuccinimide ester of K-aleyl-muramyl-L- alanine analogously to example 2; 1.52 g (88%) of compound X, R; 0.31 (A), 0.64 (B).
Found,%: C 5.63, H 8.25, N 5.87; P 2.40; Na 1,59-,
3PNa. 2,
Calculated,%: C 54.49; H 8.35; N 5.68; P 2.51, Na 1.86.
0
five
0
five
0
Immunostimulating activity of compounds 1- was studied in experiments in
vivo by ability to increase antibody formation in mice. The studies were carried out in comparison with the known immunostimulant, N-benzoyl-muramyl-L-alanyl-B-isoglutamine, which is a structural analogue of compounds 1-X. The older NMRI breeds were immunized by intraperitoneal administration of 10 mg BSA. After 9, 15 and 29 days sampled
serum and examined them for the content of antibodies to BSA using the method of passive hemagglutination. Used dose (10 mg / kg) BSA for animal recipients subimmuno712
gene, i.e. does not cause antibodies or their formation is insignificant. Additional administration of immunostimulatory compounds by per unit or after antigen administration. leads to an increase in antibody titer in serum. The immunostimulating effect of the studied compounds was evaluated using the sum of the differences of the titers | og in all three samples. The concentrations of compounds 1-X and N-benzoyl-myramil-L-alayl-β-D-isoglutamine (X1) determined the dose, upon administration of which, the amount of animals
The difference in fog credits is 10.
A-Y-0-P-0-CH2-CH-CH2-R 5 ONQ Hz.
where Y O-CH -CONHCHjCH -,
The acute toxicity of the compounds f-X was determined in mice. The immunostimulating activity and acute toxicity of the sodium salts of the derivatives of the muramyl peptides 1-X are given in the table.
20 -NHCHjCH-NH-CH (CHJ-CONHCH, CH, -; (L),
 Have
 hydrogen, o-c- (cn2) 11 -snz;
25
Rj-ShR, CONH,
tONH-CH-CONH-CH-CHzCHjCOA (L) -TH)
R, - C, -CJ-alkyl; Rj is hydrogen, CH ,; R-C, -C4-alkyl,
ABOUT
A-Y-0-P-0-CH2-CH-CH2-R 5 ONQ Hz.
where Y O-CH -CONHCHjCH -,
25
I
Р5--0-С- (
about
characterized in that the compound of the general formula
As can be seen from the table, compounds 1-X have a high immunostimulating activity in combination with low toxicity and are significantly superior in activity to the well-known immunostimulant, L-benzoyl-muramyl-L-apanyl-B-isoglutamine (XI).

权利要求:
Claims (4)
[1]
11 The invention relates to a process for the preparation of new biologically active compounds, namely, sodium salts of derivatives of muramyl peptides of the general formula, Ri-f ONH-CH-CONH-CH-CHjCH7COA (L) (D) where R (- C -, - C - alkyl, Rj is hydrogen, CH ,; R} is C, -C4-alkyl-, A--YOPO-CH-CH-CH -R ONa Rii where Y is -0-CHj, 4: ONHCH CH, -, - NHCH CHj -, -NH-CH (CH) -CONHCH CH (L) R. - hydrogen, (hg rtd and L.) l / t-CHo (CH2) i / i.-CH3 The purpose of the invention is to obtain new derivatives of muramyl peptides possessing higher immunostimulating activity in combination with low toxicity Example 1. Sodium salt of N-acetyl-muramyl-b-alanyl-B-isogluates nyl-b-alanine-2- (1,2-dipalmitoyl-5p-glycero-3-phosphoryl) -eth: ylamDa (1). To 1.0 mmol 1-o6-benzsh1-N-acetyl-4, 6- isopropylidene-muraminic acid and 0.9 mmol of L-alanyl-B-isoglutaminyl-1-, -alanine-2- (1,2-dipalmitoyl-8n-glycero-3-phosphoryl) -ethyl and in a mixture of 15 ml of dimethylformamide-, 10 ml of tetrahydrofuran and 2 ml of pyridine were added with 1.2 mmol of dicyclohexylcarbodiimide and 1.3 mmol of N-oxysuccinimide. After 24 hours, a few drops of water are added to the reaction mixture, the dicyclohec of urea is filtered off and the filtrate is evaporated to dryness in vacuo. The residue was purified by column chromatography on silica gel (Merck) using chloroform: methanol (7: 3) as eluant. The fractions containing the desired product are evaporated, a mixture of 12 MP of glacial acetic acid and 8 ml of water is added to the residue, kept at 50 ° C for 1 hour and then hydrogenated for 20 hours at room temperature and atmospheric pressure in the presence of 10% - Palladium on coal. Then the catalyst is filtered off, the filtrate is evaporated in vacuo, the residue is dissolved in -150 ml of water. The resulting solution was filtered through a Millipore teflon filtrate (5 μm). The filtrate is subjected to dialysis with stirring in an Amfikon ultrafiltration cell using an Amikon YM 10 type membrane using diaphication for sequentially 400 ml of water, 200 ml of a mixture of 0.1 M sodium phosphate buffer 0, 1 M NaCJ solution (pH 7.0), 850 ml of water. The internal dialysate is filtered through a Millipore type teflon filter (0.45 μm). The filtrate is dried liral. A total of 1.08 g (91%) of the compound, M +13.9 (C i, 0i acetic acid), is obtained. Found,%: C 53.89; H 8.63; N 6.40; P 2.22i Na 1.58. , С5, Н, „N, 0 PNa 3 Н, 0. Calculated C, 53.59; H 8.75; N 6.40; P 2.36; Na 1.75. Example
[2]
2. Sodium salt of H-acetyl-muramyl-b-alanyl-B-isoglutaminyl-b-alanine-2- (1,2-dipalmitoyl-3p-glycero-3-phosphoryl) -ethylamide (1). To a solution of 1.0 mmol of B-isoglutaminyl-b-alanine-2- (1, 2-dipalmitoyl-3p-glycero-3-phosphoryl) -ethylamide and 3.5 mmol of K-eti.pmorpholin in 25 ml of a mixture of chloroform-methanol - water (65: 25: 4) is added dropwise 1.5 mmol of N-hydroxycyclic acid N-acetyl-muramyl-b-alanine 5, O ml of dimethylacetamide. The reaction mixture is stirred at room temperature for 8 hours, 130 ml of water are added and evaporated in vacuo to remove chloroform and part of methanol. Leave the aqueous solution filtered through a Millipore-type Teflon filter (5 µm). The filtrate is dialyzed with stirring in an Amfikon ultrafiltration cell using an Amikon YM 10 type membrane using diafiltration successively against 400 MP of water, 200 mp of a mixture of 0.1 M sodium phosphate buffer –0.1 M NaCi solution (pH 7.0) and 850 ml of water The internal dialysate is filtered through a Millipore-type Teflon filter (0.45 µm). The filtrate is dried lyophilic. As a result, 1.20 g (91%) of compound 1, Rr 0.29 (chloroform - methanol - water 65: 25: 4) (A), 0.65 (chlorine form - methanol - acetic acid, water 25: 15: 4: 2) (b). For all other physicochemical characteristics, the resulting product fully corresponds to the compound obtained in Example 1. Example
[3]
3. Sodium salt of K-acetyl-muramyl-b-alanyl-B-isoglutaminyl-b-alanine-2- (1, 2 -dipalmitoyl-8n-glycero-3-phosphoryl) -ethylamide (T). 0.26 g (0.75 mmol) of N-acetyl-muramyl-b-alaicna 1.2H20 and 0.172 g (1.5 mmol) of N-oxysuccinimide are dissolved in 3.0 ml of absolute dimethyl acetamide. 0.232 g (1.13 mmol of dicyclohexylcarbodiimide) is added to the solution at OC. The reaction mixture is stirred for 8 hours and a solution of 0.445 g (0.5 mmol of B-isoglutamyl-b-alanine-2- (1,2-dipalmitoyl - Cp-glycero-3-phosphoryl) -ethylamide and 0.07 ml (0.5 mmol of triethylamine c. 12 ml of a mixture of chloro / form - methanol - water (65: 25: 4). Then the reaction mixture is stirred for 24 hours at 60 MP of ethyl acetate are added, the mixture is stirred for several minutes in an ice bath and filtered, 65 MP of water are added to the filtrate and the mixture is evaporated in vacuo to be removed and volatile organic solvents. Ostaviyis aqueous solution is dialyzed with stirring in an ultrafiltration cell of the Amikon type using an Amikon YM 10 type membrane against 200 ml of water, 100 ml of a 0.1 M sodium phosphate buffer (pH 7 , 0) and 425 ml of water. The internal dialysate is filtered through a Millipore-type teflon filter (0.45 µm. The filtrate is freeze-dried. In total, 0.546 g (83%) of compound 1, RI 0.45 (acetonitrile — water 3: 1) are obtained. For all other physico-chemical characteristics, the product obtained is fully consistent with the compound obtained in Example 1. Example 4. Sodium salt of N-acetyl-de-methylmethyl or L-L-alanyl-D-isoglutamine-2- (1, 2-dipolarto-Sn -glycero-3 -phosphoryl) -ethylamide (fl), From 1.0 mmol of B-isoglutamine-2- (1, 2 -dipalmitoyl-3n-glycero-3-phosphoryl) -thylamide -2.8 NO and 1.5 mmol N-oxysuccinimide ester. Analogously to Example 2, 1.18 g (96%) of Compound II, R, 0.29 (A), 0.65 (B) are obtained from N-acetyl-desmethyl-methyl amyl-L-alanine. Found,%: C 53.67, H 8.16; N 5.93i P 2.40; Na 1.71. С „Н, o, N50, gPNa- 2,8НгО Calculated,%: С 53.88; H 8.25; N 5.71; P 2.53; Na 1.88. Example 5. Sodium salt of M-acetyl-muramyl-b-alanyl-B-isoglutaminyl-y-hydroxy-methylcarbonyl-2- (1, 2-dipalmitoyl-3p-glycero-3-phosphoryl) -ethylamide (ly). From 1.0 mmol of B-isoglutamine-2-oxy-methylcarbonyl-2- (1, 2-dipalmitoyl-3n-glycero-3-phosphoryl) -ethyl 1 and 1.5 mmol of N-oxysuccinimide ester K-acetyl-muramyl-b -alanine analogously to Example 2, 1.20 g (92%) of the compound HZ, R, 0.28 (A), 0.68 (B) is obtained. Found,%: C 53.21; H 8.09; N 5.18; P 2.21; Na 1.58; SzvNiub N O oPNa- 3,1 Calculated,%: C 53.40; H 8.13; N 5.37; P 2.38; Na 1.78. Example 6. Sodium salt of L-acetyl-desmethylmuramyl-b-alanyl-B-of oglutamine-2- (3-palmitoyl-rac-glycero-1-phosphoryl) -ethylamide (ly), 1.0 mmol of B-isoglutamine- 2- (3-palmitoyl-rac-glycero-1-phosphoryl) ethylamide and 1.5 mmol of N-oxysucci of N-acetyl-desmethimuramyl-b-alanine nimido ester as in Example 2, 0.69 g (69%) of compound IV, R is obtained 0.47 (A). Found,%: C, 47.22; H 7.17; N 7.31; P 3.01; Na 2.14, NjO PNa- 3.2 Calculated,%: C 47.08; H 7.24; 7.04; P 3.12; - Na 2.31. P Pu M e P 7. Sodium salt of acetyl-muramyl-b-alanyl-B-isoglutaminyl-b-alanine-2- (3-palmitoyl-rac-glycero-1-phosphoryl) ethylamide f. From 1.0 mmol of B-isoglutaminyl-b-alanine-2- (3-palmitoyl-rac-glycero-l-phosphoryl) -ethyl, and 1.51 tmol N-oxysuccinimidyl ester of N-acetyl-muramyl-b-alanine is analogous to py 2 receive compound V, R O, 22 (A Found,%: C 47.71, H 7.81; N 7.55; P - 2.71; Na 2.01; C, H7gNgO, gPNa. 3.1 Calculated,%: C 47.92-, H 7.24; N 7.80; P 2.88; Na 2.1 D. Example 8. Sodium salt of L-acetyl-desmethylmuramyl-b-alanyl-B- isoglutaminyl-b-alanine-2- (l, 2 -dipalmitoyl-3p-glider-3 -phosphoryl) -ethylamide (ut), From 1.0 mmol of B-isoglutaminyl-b-apanine-2 (1, 2-dipalmitoyl- Snglycero-3-phosphorus-1) - ethylamide and 1.5 mmol of N-oxysuccinimide eff N-acetyl-de-methylmethyl or IL-L-alanine, as in Example 2, was obtained 1.065 (82%) of compound VI, R ± 0.39 (A). Found: C 53.68, H 8.02; N 6.38 ; R 2.24, Na 1.60 .. PNa-3N, 0 Calculated,%: C 53.47; H 8.14; N 6.45; R 2.38; Na 1.77. Example 9. Sodium salt of N-ace t yl-de 3-methyl-muramyl-L-alanyl-B-isoglutaminyl-b-alanine-2- (3 -p mitoyl-rac-glycero-1-phosphoryl) -et amide (vfi) Of 1.0 mmol of N-isoglyl aminyl-LI-alanine-2- (3-palmitoyl-rac-glycero ro-1 -phosphoryl) ethylamide and 1.5 mmol of N-adethyl dismu ghylmuramyl-b-alanine H-nitrophenyl ether 2 receive compound VI
[4]
4.J 0.16 (A). The yield of 0.755 g (71%). Found,%: With 47.48; H 7.09, N 7.80i P - 2.71; Na 2.01-, C z TeNbOiS PNa- 2, Calculated,%: C 47.66; H 7.19; N 7.94; P 2.93; Na 2.17. Example 10. Sodium salt of N-acetyl-myramyl-L- (xL-aminobutyters I-B-isoglutaminyl-b-ala 1In-2- (1, 2-dipalmitoyl-Zp-glycero-3-phosphoryl) -ethyl amide (VIJI) Out of 1.0 mmol of B-isoglptamine-1-alanine-2- (1, 2 -dipalmitoyl-Sn-glycero-3-phosphoryl) -ethylamide, 1.5 mmol of N-acetyl-mymyl-L-oi, -ai of hydrochloric acid, 2.5 mmole of dimecy logixylcarbodiimide and 3.0 mmole N of oxysucdinimide, analogously to the example, the compound Vlll, RL 0.32 (A) was found.% C 53.74; H 8.23; 6.04; P 2.18; Na-1.54, Compound of NbO ,, PNa- 3.93H20 Calculated,%: C 53.56; H, 8.18; 6.25; P, 2.31; Na, 1.71. Example 11 The sodium salt of propionyl-nopyramyl-L-alanyl-Bisoglutaminsh1-b-al; a nin-2- (1, 2 -dialmitoyl-3n-glycero-3-phosphoryl) ethylamide (IX). Out of 1.0 mmol of B-isoglutaminyl-L alanine-2- (1, 2 dipropyl, itoyl-Sn-glycol -3-phosphoryl) -ethylamide and 1.5 mmol of N-propionyl-normuramyl-b-alanine N-hydroxyphthalimide ester, as in Example 2, 1.15 g (87%) of compound IX, R 0.16 (A), (CO , 547 yccyclic acid). Found: C 53.31; H 8.26; N 6.14; P 2.15; Na 1.55. C5gH (o8NgO ,, PNa 3.5: Calculated,%: C 53.53, H 8.17; N 6.35; P 2.34, Na 1.74. Example 12. Sodium salt of N-acetyl-mypamyl-L - alaanil-S-isoglutamine-2- (1, 2-dipl of itoyl-3n-glydero-3-phosphoryl) -ethylamide (X). Of 1.4 mmol of B-isogluta1 shn-2- (1,2-dipalmitoyl -Wn-glycero-3-phosphoryl) -ethylamide and 2.0 mmol of the N-oxysucdinimide ester of K-a1-yl-muramyl-L-alanine, as in Example 2, 1.52 g (88%) of the compound X, R; 0.31 ( A), 0.64 (B). Found,%: C 5.63, H 8.25, N 5.87; R 2.40; Na 1.59 -,,, 3PNa. 2, Calculated,%: C 54.49; H 8.35; N 5.68; P 2.51, Na 1.86. Immunostimulating activity of compounds 1- was studied in in vivo experiments with the ability to increase to produce antibodies in mice. The studies were carried out in comparison with the known immunostimulant - N-benzoyl-muramyl-b-alanyl-B-isoglutamine, which is a structural analogue of compounds 1-X. NMRI was immunized by intraperitoneal administration of 10 mg BSA. After 9, 15 and 29 days, samples of blood serum were collected and examined for the content of antibodies to BSA using the method of passive hemagglutination. At the used dose (10 mg / kg) BSA for animal recipients of subimmuno. As can be seen from the table, compounds 1-X have a high immunostimulatory activity combined with low toxicity and the activity significantly exceeds the well-known immunostimulant - L-benzoyl-muramyl-b -apanyl-B-isoglutamine (XI). The invention The method of obtaining the sodium salts of derivatives muramyl peptides of General formula
Р5--0-С- (
about
I
characterized in that the compound of the general formula CH20R6 ORa t, c (n COL and R have the indicated meanings and R is each separately OR or OR together and 3 definitions; and Rg is hydrogen, benzyl; L is OH or a residue of the formula NH-CH (R,) - COOX, (L) has the indicated meanings; hydrogen, p-nitrophenyl, pentachlorophenip.
9, 127790610
condensed in inert organic-W-CH (K) -CO-,
solvent or solvent mixture (gt)
lei at a temperature of from 0 ° C to the rooms - the specified values
temperature with a compound of the general condition that E is -NH-CH (R J-COOX, formula 5
CCWHi if L is OH and E is hydrogen,
E-wH-CH-CHiCHiCO-T-o-p-o-cHr-at-cHri if L is -Sh-CH (EZ) -COOH,
P) HE R4
where Y, R, and Rj have the indicated knowledge-splitting, if necessary, of the immersion; protective groups and the resulting
E — hydrogen or residue is converted to its sodium
formulas. ,salt.
Sh

类似技术:

---

公开号 | 公开日 | 专利标题

---

SU1277906A3|1986-12-15|Method of producing sodium salts of muramylpeptide derivatives

---

US4082736A|1978-04-04|Novel immunological adjuvant compounds and methods of preparation thereof

---

US4082735A|1978-04-04|Novel immunological adjuvant compounds and methods of preparation thereof

---

DE2728324C2|1988-07-07|

---

KR950007923B1|1995-07-21|Sialic acid derivatives having active carbonil group

---

NL8802595A|1989-05-16|DERIVATIVES OF MONOFOSPHORYL-LIPIDE A AND METHOD FOR THE PREPARATION THEREOF

---

DE3211263A1|1983-01-27|HUMAN INTERFERON RELATED PEPTIDES, ANTIGENS AND ANTIBODIES, AND METHOD FOR THE PRODUCTION THEREOF

---

EP0228612A2|1987-07-15|A derivative of alpha, alpha-trehalose and a process for preparing the same

---

CA1174232A|1984-09-11|Immunologically active dipeptidyl 4-o-,6-o-acyl-2-amino-2-deoxy-d-glucose derivatives and methodsfor their preparation

---

RU2074192C1|1997-02-27|Muramyldipeptide derivatives, antiinfluenza vaccine

---

EP0060999B1|1985-08-21|Galactopyranosides, process for their preparation and their use as antigens or immuno absorbents

---

DE2718010C2|1990-11-08|

---

US4101649A|1978-07-18|Hydrosoluble agents having non specific immunodepressive properties

---

DE2730549A1|1978-01-19|PEPTIDE DERIVATIVES AND THEIR PRODUCTION

---

JP4226324B2|2009-02-18|Carboxylic acid type lipid

---

CA1185236A|1985-04-09|Immunologically active dipeptidyl saccharides andmethods of preparation

---

EP0096292B1|1986-07-23|Beta-d-galactose derivatives, process for their production and their use

---

GB2053232A|1981-02-04|Dipeptides their preparation and the medicaments in which they are present

---

EP0175290A2|1986-03-26|Glycopeptides, method for their preparation and their use

---

DD145274A5|1980-12-03|METHOD FOR THE PREPARATION OF NEW COMPOUNDS OF THE MURAMYLPEPTIDE TYPE

---

US4377570A|1983-03-22|Immunologically active dipeptidyl saccharides and methods of preparation

---

EP0073834B1|1986-06-25|Water-soluble cholesterol derivatives

---

DD217210A1|1985-01-09|PROCESS FOR PREPARING L-ALANYL-D-ISOGLUTAMINYL ADAMANTYLAMIDE

---

Ponpipom et al.1983|Methyl β-glycosides of N-acetyl-6-O-| muramyl-l-alanyl-d-isoglutamines, and their conjugates with meningococcal group C polysaccharide

---

FI59987C|1981-11-10|FOERFARANDE FOER SYNTETISERING AV AMINOSYRA-AMIDER AV DOPAMIN VILKA HAR BLODTRYCKSSAENKANDE OCH BLODKAERLEN UTVIDGANDE EGENSKAPER

同族专利:

---

公开号 | 公开日

---

DK319480A|1981-01-26|

---

DE3068304D1|1984-07-26|

---

FI802294A|1981-01-26|

---

HK85787A|1987-11-27|

---

AU6658181A|1982-11-04|

---

NO157177C|1988-02-03|

---

PL127481B1|1983-10-31|

---

MX9203368A|1992-09-01|

---

CA1183129A|1985-02-26|

---

DD153843A5|1982-02-03|

---

IE50145B1|1986-02-19|

---

GR69314B|1982-05-14|

---

PL225870A1|1981-05-08|

---

IL60676A|1984-10-31|

---

NZ194432A|1983-09-02|

---

NO802200L|1981-01-26|

---

CY1381A|1987-12-18|

---

PT71607A|1980-08-01|

---

JPS6356239B2|1988-11-07|

---

CS526280A3|1992-06-17|

---

ZA804487B|1981-07-29|

---

US4406890A|1983-09-27|

---

KR840001617B1|1984-10-11|

---

FI75578B|1988-03-31|

---

AU541147B2|1984-12-20|

---

CS276965B6|1992-11-18|

---

DK161025C|1991-10-28|

---

EP0025495A1|1981-03-25|

---

US4414204A|1983-11-08|

---

IE801533L|1981-01-25|

---

EP0025495B1|1984-06-20|

---

FI75578C|1988-07-11|

---

HU188861B|1986-05-28|

---

MY8700554A|1987-12-31|

---

SG38187G|1988-01-15|

---

IL60676D0|1980-09-16|

---

SU1277905A3|1986-12-15|

---

NO157177B|1987-10-26|

---

ES493633A0|1981-07-01|

---

PL131613B1|1984-12-31|

---

JPS5649397A|1981-05-02|

---

ES8105971A1|1981-07-01|

---

AU6078880A|1981-01-29|

---

DK161025B|1991-05-21|

---

KR830003511A|1983-06-21|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

NL7308450A|1972-06-20|1973-12-27|

---

US4001395A|1972-06-20|1977-01-04|Agence Nationale De Valorisation De La Recherche |Hydrosoluble extracts of mycobacteria|

---

US4186194A|1973-10-23|1980-01-29|Agence Nationale De Valorisation De La Recherche |Water soluble agents effective as immunological adjuvants for stimulating, in the host the immune response to various antigens and compositions, notably vaccines containing said water soluble agents|

---

CH613709A5|1975-12-10|1979-10-15|Ciba Geigy Ag|Process for the preparation of glucosamine derivatives|

---

US4082735A|1976-04-26|1978-04-04|Syntex Inc.|Novel immunological adjuvant compounds and methods of preparation thereof|

---

US4082736A|1976-04-26|1978-04-04|Syntex Inc.|Novel immunological adjuvant compounds and methods of preparation thereof|

---

GB1563561A|1976-06-23|1980-03-26|Daiichi Seiyaku Co|Muramyldipeptide derivatives and process for the preparation thereof|

---

FR2368282B1|1976-10-22|1980-10-17|Anvar|

---

US4268505A|1978-04-13|1981-05-19|Kureha Kagaku Kogyo Kabushiki Kaisha|Pharmaceutical composition comprising a nitrogen-containing polysaccharide and an antibiotic agent, and a method of treating an infectious disease therewith|

---

FI803077A|1979-10-12|1981-04-13|Ciba Geigy Ag|FOERFARANDE FOER FRAMSTAELLNING AV MYRAMYLPEPTIDER|GB1582884A|1977-05-19|1981-01-14|Beecham Group Ltd|Clavulanic acid derivatives their preparation and use|

---

DK330880A|1979-08-03|1981-02-04|Beecham Group Ltd|PROCEDURE FOR THE PREPARATION OF CLAVULANIC ACID DERIVATIVES|

---

FI803077A|1979-10-12|1981-04-13|Ciba Geigy Ag|FOERFARANDE FOER FRAMSTAELLNING AV MYRAMYLPEPTIDER|

---

EP0053893B1|1980-12-09|1985-03-20|Beecham Group Plc|Derivatives of clavulanic acid, their preparation and their use|

---

US4562182A|1980-12-23|1985-12-31|Beecham Group P.L.C.|Compounds containing beta-lactams|

---

EP0056560A1|1981-01-19|1982-07-28|Ciba-Geigy Ag|Active antibiotic compositions, process for their manufacture and process for the antibiotic activity of antibiotics|

---

GR78246B|1981-01-23|1984-09-26|Ciba Geigy Ag|

---

US5334583A|1982-07-23|1994-08-02|Ciba-Geigy Corp.|Use of sugar derivatives for the prophylaxis and treatment of virus infections|

---

EP0102319B1|1982-07-23|1987-08-19|Ciba-Geigy Ag|Prophylactic and therapeutic use of muramyl peptides and their analogues against viral infections|

---

US5189017A|1982-07-23|1993-02-23|Ciba-Geigy Corporation|Use of sugar derivatives for the prophylaxis and treatment of virus infections|

---

AT23536T|1982-07-23|1986-11-15|Ciba Geigy Ag|NEW MURAMYL PEPTIDES AND METHOD FOR THEIR PRODUCTION.|

---

US4746651A|1983-11-01|1988-05-24|Scripps Clinic And Research Foundation|Antimicrobial chemotherapeutic potentiation using substituted nucleoside derivatives|

---

US5171568A|1984-04-06|1992-12-15|Chiron Corporation|Recombinant herpes simplex gb-gd vaccine|

---

FR2564096B1|1984-05-11|1988-02-19|Anvar|LIPOPHILIC DERIVATIVES OF MURAMYLPEPTIDES HAVING MACROPHAGE ACTIVATION PROPERTIES, COMPOSITIONS CONTAINING THEM AND PROCESS FOR OBTAINING THE SAME|

---

EP0169812B1|1984-07-25|1989-08-23|Ciba-Geigy Ag|Phosphatidyl compounds, process for their preparation and their use|

---

EP0174912A3|1984-09-13|1986-06-04|Ciba-Geigy Ag|Phosphorus compounds, process for their preparations and their use|

---

CA1260393A|1984-10-16|1989-09-26|Lajos Tarcsay|Liposomes of synthetic lipids|

---

GB8524001D0|1985-09-30|1985-11-06|Glaxo Group Ltd|Pharmaceutical composition|

---

US4873322A|1986-01-24|1989-10-10|Ciba-Geigy Corporation|Saccharide derivatives and processes for their manufacture|

---

US4916118A|1986-08-18|1990-04-10|Board Of Regents, The University Of Texas System|Pharmaceutical administration systems containing chemotactic peptides|

---

US5149529A|1988-04-08|1992-09-22|Board Of Trustees Of Leland Chiron Corporation|Compositions and treatment for herpes simplex|

---

US4950645A|1988-07-08|1990-08-21|Immunotherapeutics, Inc.|Composition for macrophage activation|

---

US5416070A|1988-07-08|1995-05-16|Immunotherapeutics, Inc.|Composition for macrophage activation|

---

US4994440A|1989-02-13|1991-02-19|Creaven Patrick J|Method for the treatment of renal cell carcinoma|

---

GB9320820D0|1993-10-08|1993-12-01|Biokine Tech Ltd|Compounds for medicinal use|

---

US6156319A|1994-07-25|2000-12-05|The Trustees Of The University Of Pennsylvania|Soluble herpesvirus glycoprotein complex vaccine|

---

US6080427A|1997-04-17|2000-06-27|Bristol-Myers Squibb Company|Cefadroxil monohydrate tablet formulation|

---

AUPP059897A0|1997-11-27|1998-01-08|Fujisawa Pharmaceutical Co., Ltd.|New use of bicozamycin|

---

US20040029842A1|2001-12-18|2004-02-12|Gardner Wallace J.|Triglyceride lowering, common cold and pneumonia prevention composition comprising tetracycline, and methods of treating or preventing diseases using same|

---

AU2004262506A1|2003-02-28|2005-02-17|National Institutes Of Health|Compositions, methods and kits relating to poxvirus subunit vaccines|

---

US20050079187A1|2003-10-14|2005-04-14|Gardner Wallace J.|Composition, kit and method for reducing plaque formation, tooth decay and incidence of caries|

---

CN101501055B|2005-06-23|2016-05-11|贝勒医学院|The adjusting of negativity immune-regulating factor and immunotherapy application|

---

CN101437834B|2004-07-19|2012-06-06|贝勒医学院|Modulation of cytokine signaling regulators and applications for immunotherapy|

---

US8367052B2|2007-03-26|2013-02-05|General Regeneratives Holdings Inc.|Methods for promoting protection and regeneration of bone marrow using CXCL9 and anti-CXCL9 antibodies|

---

EP2222344A4|2007-11-30|2012-11-07|Baylor College Medicine|Dendritic cell vaccine compositions and uses of same|

---

PT2411521E|2009-03-25|2015-04-21|Univ Texas|Compositions for stimulation of mammalian innate immune resistance to pathogens|

---

US9808504B2|2009-09-22|2017-11-07|Yale University|Immunogenic epitopes as targets for universal cancer vaccines|

---

EP2741785B1|2011-07-12|2018-09-05|Philadelphia Health and Education Corporation|Novel clostridium difficile dna vaccine|

---

RU2491922C1|2012-04-26|2013-09-10|Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования Курская государственная сельскохозяйственная академия имени профессора И.И. Иванова|Method for increasing biocidal and therapeutic action of suspension-cream with enrofloxacin|

---

RU2527330C2|2012-07-05|2014-08-27|Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования Курская государственная сельскохозяйственная академия имени профессора И.И. Иванова Министерства сельского хозяйства Российской Федерации|Method for increasing biocidal and therapeutic action of suspension-cream with metronidazole|

---

EP2951199A4|2013-01-31|2016-07-20|Univ Jefferson|Fusion proteins for modulating regulatory and effector t cells|

---

WO2015116178A1|2014-01-31|2015-08-06|Thomas Jefferson University|Fusion proteins for modulating regulatory and effector t cells|

---

WO2016044839A2|2014-09-19|2016-03-24|The Board Of Regents Of The University Of Texas System|Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds|

---

US10610564B2|2015-02-26|2020-04-07|Stc.Unm|IRGM and precision autophagy controls for antimicrobial and inflammatory disease states and methods of detection of autophagy|

---

CN108883080B|2015-12-15|2021-12-21|巴拉特生物技术国际有限公司|Muramyl peptide derivative compounds, their synthesis and use thereof|

---

WO2020140007A1|2018-12-28|2020-07-02|University Of Rochester|Gene therapy for best1 dominant mutations|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

CH689379|1979-07-25|

---

AU66581/81A|AU6658181A|1979-07-25|1981-01-23|Increasing antibiotic action of antibiotics|

---